These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 8923849)

  • 1. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption.
    Papapoulos SE; Frölich M
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3993-7. PubMed ID: 8923849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P; Gineyts E; Schaffer AV; Seaman J; Delmas PD
    Arthritis Rheum; 1998 Feb; 41(2):354-60. PubMed ID: 9485094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L; Peris P; Guañabens N; Vidal S; Quintó L; Monegal A; Pons F; Ballesta AM; Muñoz-Gómez J
    Rheumatology (Oxford); 2004 Jul; 43(7):869-74. PubMed ID: 15054158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone.
    Alexandersen P; Peris P; Guañabens N; Byrjalsen I; Alvarez L; Solberg H; Cloos PA
    J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary collagen crosslink excretion: a better index of bone resorption than hydroxyproline in Paget's disease of bone?
    Hamdy NA; Papapoulos SE; Colwell A; Eastell R; Russell RG
    Bone Miner; 1993 Jul; 22(1):1-8. PubMed ID: 8219934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Monegal A; Bedini JL; Deulofeu R; Martinez de Osaba MJ; Muñoz-Gomez J; Rivera-Fillat F; Ballesta AM
    J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
    Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F
    Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate.
    O'Doherty DP; Bickerstaff DR; McCloskey EV; Hamdy NA; Beneton MN; Harris S; Mian M; Kanis JA
    J Bone Miner Res; 1990 May; 5(5):483-91. PubMed ID: 2195845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone.
    Reid IR; Davidson JS; Wattie D; Wu F; Lucas J; Gamble GD; Rutland MD; Cundy T
    Bone; 2004 Jul; 35(1):224-30. PubMed ID: 15207761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
    Garnero P; Gineyts E; Riou JP; Delmas PD
    J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone.
    Garnero P; Christgau S; Delmas PD
    Bone; 2001 May; 28(5):461-4. PubMed ID: 11344044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of bisphosphonates on new and traditional markers of bone resorption.
    Pedrazzoni M; Alfano FS; Gatti C; Fantuzzi M; Girasole G; Campanini C; Basini G; Passeri M
    Calcif Tissue Int; 1995 Jul; 57(1):25-9. PubMed ID: 7671161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Deoxypyridinoline and other biochemical markers of bone resorption in distinct pathologies].
    Rivero Marcotegui A; Palacios Sarrasqueta M; Grijalba Uche A; Martínez Rodríguez JL; Sorbet Zubiría MJ; García Merlo S
    Rev Clin Esp; 1997 Jun; 197(6):389-92. PubMed ID: 9304127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical assessment of Paget's disease of bone.
    Shankar S; Hosking DJ
    J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease.
    Alvarez L; Guañabens N; Peris P; Vidal S; Ros I; Monegal A; Bedini JL; Deulofeu R; Pons F; Muñoz-Gomez J; Ballesta AM
    Bone; 2001 Nov; 29(5):447-52. PubMed ID: 11704497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links.
    Randall AG; Kent GN; Garcia-Webb P; Bhagat CI; Pearce DJ; Gutteridge DH; Prince RL; Stewart G; Stuckey B; Will RK; Retallack RW; Price RI; Ward L
    J Bone Miner Res; 1996 Aug; 11(8):1176-84. PubMed ID: 8854254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity.
    Alvarez L; Peris P; Pons F; Guañabens N; Herranz R; Monegal A; Bedini JL; Deulofeu R; Martínez de Osaba MJ; Muñoz-Gómez J; Ballesta AM
    Arthritis Rheum; 1997 Mar; 40(3):461-8. PubMed ID: 9082934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term intravenous therapy with Neridronate in Paget's disease.
    Adami S; Bevilacqua M; Broggini M; Filipponi P; Ortolani S; Palummeri E; Ulivieri F; Nannipieri F; Braga V
    Clin Exp Rheumatol; 2002; 20(1):55-8. PubMed ID: 11892710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
    Adami S; Salvagno G; Guarrera G; Montesanti F; Garavelli S; Rosini S; Lo Cascio V
    Calcif Tissue Int; 1986 Oct; 39(4):226-9. PubMed ID: 2947663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.